← Leaderboards
Philippe Marambaud
Feinstein Institute For Medical Research
$7,652,037
Attributed
$10,059,975
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,059,975 · 5
By mechanism
R01$10,059,975 · 5
Top collaborators
- Ping Wang5 shared
- Stryder Medoah Meadows4 shared
Most similar at Feinstein Institute For Medical Research
Same institution · by research overlap
- Ping Wang$26,716,102
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionAlzheimer&AposPathway InteractionsPathologyPathogenesisMediatingIn VivoKnockout MiceMouse ModelBrainMolecularDefectBaseLungBlood VesselsHereditary Hemorrhagic TelangiectasiaProteinsEndothelial CellsGeneticAnimal ModelArteriovenous MalformationLoss Of FunctionBloodOrgan
Grant awards (22)
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$671,700
R01 · FY2025 · HL
Therapeutic Potential of ALK1 Activating Drugs in HHT Models$569,892
R01 · FY2025 · HL · contact PI
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$664,047
R01 · FY2024 · HL
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP$418,750
R01 · FY2024 · AA
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$683,964
R01 · FY2023 · HL
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP$418,750
R01 · FY2023 · AA
mTOR and VEGFR2 pathways in HHT pathogenesis$418,750
R01 · FY2023 · HL · contact PI
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$702,416
R01 · FY2022 · HL
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP$418,750
R01 · FY2022 · AA
mTOR and VEGFR2 pathways in HHT pathogenesis$418,750
R01 · FY2022 · HL · contact PI
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP$418,750
R01 · FY2021 · AA
mTOR and VEGFR2 pathways in HHT pathogenesis$418,750
R01 · FY2021 · HL · contact PI
Therapeutic Potential of ALK1 Activating Drugs in HHT Models$412,500
R01 · FY2021 · HL · contact PI
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP$418,750
R01 · FY2020 · AA
mTOR and VEGFR2 pathways in HHT pathogenesis$418,750
R01 · FY2020 · HL · contact PI
Therapeutic Potential of ALK1 Activating Drugs in HHT Models$412,500
R01 · FY2020 · HL · contact PI
Therapeutic Potential of ALK1 Activating Drugs in HHT Models$401,336
R01 · FY2019 · HL · contact PI
Therapeutic Potential of ALK1 Activating Drugs in HHT Models$401,533
R01 · FY2018 · HL · contact PI
Mechanisms of regulation of amyloid-beta metabolism by CALHM1$345,425
R01 · FY2016 · AG · contact PI
Mechanisms of regulation of amyloid-beta metabolism by CALHM1$335,062
R01 · FY2015 · AG · contact PI
Mechanisms of regulation of amyloid-beta metabolism by CALHM1$345,425
R01 · FY2014 · AG · contact PI
Mechanisms of regulation of amyloid-beta metabolism by CALHM1$345,425
R01 · FY2013 · AG · contact PI